EUCTR2021-001235-12-BG进行中（未招募）1 期
GULLIVER-2 - a single (open-label) and repeat dose (randomised, placebo-controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with hepatic impairment (Child Pugh B and Child Pugh C)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Males or females, of any race, = 18 and = 75 years of age at enrolment
- •2.Body mass index (BMI) of = 18–40 kg/m2
- •3.Participants with hepatic impairment:
- •a.PART 1 and PART 2: Moderate hepatic impairment, as defined by the Child–Pugh score (Child-Pugh B) who exhibit physical signs consistent with stable hepatic impairment and free of significant medical disorders unrelated to their hepatic disorder and are on stable concomitant medication for 2 weeks prior and for the duration of this study.
- •b.PART 3: Severe hepatic impairment as defined by the Child–Pugh score (Child Pugh C) who exhibit physical signs consistent with stable hepatic impairment and free of significant medical disorders unrelated to their hepatic disorder and are on stable concomitant medication for 2 weeks prior and for the duration of this study.
- •4.Healthy participants (controls) in PART 1 and PART 3:
- •a.Healthy as determined by the investigator, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac assessment
- •b.Match at least one of the participants with moderate or severe hepatic impairment with respect to gender, age (±10 years), and body mass index (BMI) ± 15% (ensure every participant with hepatic impairment has at least 1 matched control.)
- •5.Women of non-childbearing potential defined as permanently sterile or postmenopausal
- •6.Males will agree to use contraception throughout the study and until 90-days after the Follow-up visit
- •7.Male participants must agree to refrain from sperm donation from the date of Randomisation (Day 1) until 90 days after the Follow up visit
- •8.At screening, and baseline, vital signs which are within the following ranges:
- •Systolic blood pressure: = 90 and = 150 mm Hg
- •Diastolic blood pressure: = 50 and = 95 mm Hg
- •Pulse rate: = 40 and = 100 Beats Per Minute (BPM)
- •9.Able to comprehend and willing to sign an ICF and to abide by the study restrictions
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •All parts and all groups (control healthy volunteers and hepatic impairment)
- •1.History of an organ transplant, including a remote history of bone marrow transplant.
- •2.History of febrile illness within 7 days prior to the first dose of study drug or participants with evidence of active infection.
- •3.Use of any oral glucocorticoids at any dose within 30 days prior to Screening and until study completion .
- •4.Have previously completed or withdrawn from a study investigating GB1211 and have previously received the investigational product. (applicable for Part 1 and Part 3 only)
- •5.Participant who, in the opinion of the Investigator (or Designee), should not participate in this study.
- •6.Vulnerable/institutionalised patients.
- •7.Patients related to Principal Investigator (PI)/site staff.
- •8.If female, the participant is of child-bearing potential.
- •9.Participation in a clinical study involving administration of an investigational agent e.g. new chemical entity or a biological product in the past 90 days (or 5 multiples of half-life, whichever is longer) prior to dosing.
- •10.Medical history of cardiac disease and/or clinically significant ECG abnormalities. An abnormal ECG is defined as PR > 220 msec, QRS complex >120 msec, QTcF > 450 msec (males) and > 470msec (females), or any other morphological changes, other than nonspecific T-wave changes.
- •11.Donation or loss of = 400 mL blood or plasma less than 4 weeks prior to screening, or longer if required by local regulations.
- •12.Positive HIV test.
- •13.Have received live vaccine(s) within 30 days prior to Screening or who will require a vaccine(s) and until study completion.
- •14.Use of any medications/products that may inhibit biliary excretion, e.g. bile salt chelators, mycophenolic acid, warfarin, and digoxin, within 30 days prior to Screening and until study completion.
- •15.Use of any medications/products that may inhibit renal excretion; e.g. cimetidine, pyrimethamine, dolutegravir, probenecid, within 30 days prior to Screening and until study completion.
- •16.Use of any medications/products that are known inhibitors of P-gp (e.g. clarithromycin, fostamatinib, quinidine, quinine) and inducers of P-gp (e.g. carbmazepine, rifampin, St. John’s wort) within 30 days prior to Screening and until study completion.
- •Additional exclusion criteria for matched healthy control subjects:
- •17.Use of any prescription or non-prescription medication (OTC), herbal medication, dietary supplements or vitamins during 30 days prior to dosing.Acetaminophen is acceptable.
- •18.History or presence of liver disease or liver injury as indicated by an abnormal liver function profile such as AST, ALT, alkaline phosphate, or serum bilirubin
- •19.A positive Hepatitis C test or a positive Hepatitis B surface antigen (HBsAg)
- •20.Estimated glomerular filtration rate (eGFR) < 80 mL/[min*1.73 m² (estimated using the Modification of Diet in Renal Disease [MDRD] equation) at Screening
- •Additional exclusion criteria for hepatic impaired subjects:
- •Participants meeting any of the following exclusion criteria are not to be enrolled in the study/randomised to treatment:
- •21.History of any known serious disease (such as cancer, except skin basal cell carcinomas, major infection, clinically significant gastrointestinal disorder, major autoimmune disease) or other disease which in the Investigator’s opinion would exclude the patient from the study
- •22.Estimated glomerular filtration rate (eGFR) < 40 mL/[min*1.73 m²] (estimated using the MDRD equation) at
研究者
相似试验
已完成
不适用
A randomized, open-label, single-dose parallel-group trial to determine the pharmacokinetics and safety of GP2017 following a single subcutaneous injection by an autoinjector or by a pre-filled syringe in healthy male subjectsautoimmune diseasesincluding rheumatoid arthritis and psoriasis10003816NL-OMON42002Hexal AG108
招募中
不适用
Comparing pharmacokinetics of YH14659 and two constituents coadministration in healthy maleDiseases of the circulatory systemKCT0000413Yuhan60
招募中
不适用
The pharmacokinetic characteristics and safety of Rap18001 in postmenopausal femaleDiseases of the musculo-skeletal system and connective tissueKCT0004153Chonbuk National University Hospital6
已完成
不适用
An open-label, randomized, single-dose, 2-sequence, 2-period, cross-over phase 1 study under fasting state to evaluate the safety and pharmacokinetics of DKB19003” in healthy adult volunteersKCT0006103Dongkoo Bio & Pharma40
已完成
Unknown
Phase 1 study to Evaluate the Effect of Food on Investigational Product(AD-109) in Healthy Adult VolunteersKCT0009335Addpharma36